Citius Pharmaceuticals (FRA:47N) Marketable Securities : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Citius Pharmaceuticals Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Citius Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2024 was €0.00 Mil.

Citius Pharmaceuticals Marketable Securities Historical Data

The historical data trend for Citius Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Pharmaceuticals Marketable Securities Chart

Citius Pharmaceuticals Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Marketable Securities

Get a 7-Day Free Trial

Citius Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial															-	-	-	-	-

Citius Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Citius Pharmaceuticals (FRA:47N) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Citius Pharmaceuticals Marketable Securities Related Terms

Thank you for viewing the detailed overview of Citius Pharmaceuticals's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Pharmaceuticals (FRA:47N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Citius Pharmaceuticals Inc (FRA:47N) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

CTXR:USA 47N:Germany

Address

11 Commerce Drive, First Floor, Cranford, NJ, USA, 07016

Website

http://www.citiuspharma.com

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Citius Pharmaceuticals (FRA:47N) Headlines

No Headlines